Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Patients with immune thrombocytopenia and antiplatelet antibodies show increased platelet activation and desialylation

Elena Monzon Manzano, Paula Acuña, María Teresa Alvarez-Román et al. Nov 03, 2025 pp. 4792-4792 10.1182/blood-2025-4792

Abstract Background Antiplatelet autoantibodies contribute to ITP pathogenesis by enhancing platelet clearance through multiple mechanisms....

Factors associated with remote healthcare utilization in MM patients undergoing autologous stem cell transplantation

Molly Benson, Anna Howard, Isabel Concepcion et al. Nov 03, 2025 pp. 2632-2632 10.1182/blood-2025-2632

Abstract Introduction: High-dose melphalan followed by autologous stem cell transplantation (HDM/ASCT) remains a cornerstone of multiple mye...

Liquid-biopsy mutation landscape and its concordance with skin biopsies in cutaneous T-cell lymphoma

Yoni Sacknovitz, Maher Albitar, Sara Suhl et al. Nov 03, 2025 pp. 561-561 10.1182/blood-2025-561

Abstract Introduction: Liquid biopsy (LBx) is widely utilized for clinical evaluation and therapeutic monitoring in solid and hematologic ma...

CXCR4 antagonism reduces pneumonia severity in a pharmacological mouse model of CXCR2 loss-of-function-mediated neutropenia.

Jacob Bledsoe, Robert Johnson, Chi Nguyen et al. Nov 03, 2025 pp. 2982-2982 10.1182/blood-2025-2982

Abstract CXCR4 Antagonism Reduces Pneumonia Severity in a Pharmacological Mouse Model of CXCR2 Loss-of-Function-Mediated Neutropenia Robert...

Efficacy of erythropoietin and intravenous iron for treatment of critical anemia in patients who decline blood transfusions for religious reasons

Danielle Olonoff, David Levitz Nov 03, 2025 pp. 4919-4919 10.1182/blood-2025-4919

Abstract Background: Severe anemia is a common medical emergency causing impaired oxygen delivery to vital tissues and organs. Prompt recogn...

Cladribine, idarubicin, and AraC (CLIA) combined with a FLT3 inhibitor in patients with newly diagnosed FLT3-mutated Acute Myeloid Leukemia: A pooled analysis of prospective trials

Hannah Goulart, Naszrin Arani, Naval Daver et al. Nov 03, 2025 pp. 1678-1678 10.1182/blood-2025-1678

Abstract Introduction The incorporation of FLT3 inhibitors, cladribine, and high-dose cytarabine have been shown to improve outcomes in pts...

Efficacy and safety of low-dose vs. standard-dose direct oral anticoagulants for secondary prevention of venous thromboembolism: A systematic review and meta-analysis

Ursula Medeiros Araujo de Matos, Moana Divina Da Silva Santiago, Ritika Vankina et al. Nov 03, 2025 pp. 1351-1351 10.1182/blood-2025-1351

Abstract Introduction: Extended anticoagulation therapy is recommended for patients with venous thromboembolism (VTE) at high risk of recurr...

Systemic mastocytosis with associated lymphoid neoplasms (SM-ALN): A distinct subset with indolent clinical course and favorable outcomes

Angel Luis OROSCO TTAMINA, Javier Muñoz, Katalin Kelemen et al. Nov 03, 2025 pp. 7315-7315 10.1182/blood-2025-7315

Abstract Background: The coexistence of systemic mastocytosis (SM) and lymphoid neoplasms is rare and remains poorly def...

The efficacy and safety of homoharringtonine combined with venetoclax and azacitidine in primary refractory and relapsed/refractory acute myeloid leukemia

Zhenshu Xu, Ping Weng, Qiaoqiao Song et al. Nov 03, 2025 pp. 6953-6953 10.1182/blood-2025-6953

Abstract Background: Primary refractory and relapsed/refractory acute myeloid leukemia (AML) are associated with dismal outcomes, posing gre...

HDAC and CDK inhibitor combinations suppress neutrophil activation in myeloma

Snehal M Gaikwad, Tyler Peat, Wendy Du Bois et al. Nov 03, 2025 pp. 7475-7475 10.1182/blood-2025-7475

Abstract Neutrophils foster a pro-tumorigenic microenvironment in multiple myeloma (MM) by releasing inflammatory cytokines, immunosuppressi...

Image-based classification of lymphocyte subsets from routine blood smears reveals distinct immune dynamics after CAR-T infusion

Sean Paulsen, Greg Goldgof, Chad Vanderbilt et al. Nov 03, 2025 pp. 4354-4354 10.1182/blood-2025-4354

Abstract Background Chimeric antigen receptor T-cell (CAR-T) therapy is an established treatment for hematological malig...

Central nervous system involvement in Mantle Cell Lymphoma: A retrospective multicenter cohort study from the spanish geltamo group

Mariana Bastos-Oreiro, Alba Cabirta, Amanda Perez et al. Nov 03, 2025 pp. 3585-3585 10.1182/blood-2025-3585

Abstract Background: Central nervous system (CNS) involvement in mantle cell lymphoma (MCL) is an uncommon but clinically significant event,...

Impact of sociodemographic factors on survival outcomes in chronic myeloid leukemia in the United States: A time-trend analysis

Qais Bin Abdul Ghaffar, Jorge Cortés, Ravi Bhatia et al. Nov 03, 2025 pp. 6396-6396 10.1182/blood-2025-6396

Abstract Introduction: Chronic myeloid leukemia (CML) is a clonal stem cell malignancy defined by the BCR::ABL1 fusion. Although outcomes in...

Mosunetuzumab with response-driven lenalidomide augmentation achieves high response rates and immune reprogramming in untreated follicular and marginal zone lymphoma: A multicenter Phase 2 trial

Adam Olszewski, Matthew Matasar, Scott Huntington et al. Nov 03, 2025 pp. 1003-1003 10.1182/blood-2025-1003

Abstract Background:Mosunetuzumab (Mosun) is a CD20xCD3 bispecific antibody with high efficacy in treatment of relapsed/refractory follicula...

Trends in death from multiple myeloma with concomitant diabetes mellitus in the USA

Mohana Chakkera, Jia Yi Tan, Lim Ghee Kheng et al. Nov 03, 2025 pp. 7528-7528 10.1182/blood-2025-7528

Abstract Background Multiple myeloma (MM) is a cancer of plasma cells that accounts for about 10% of all hematologic cancers. With the globa...

The 10-minute targeted geriatric assessment (10-TaGA), a 10-domain-to-one-score tool, predicts early death in intensively treated older AML patients: First results from a multicenter study

Frederico Lisboa Nogueira, Olga Laura Sena Almeida, Maria Aparecida Camargos Bicalho et al. Nov 03, 2025 pp. 1600-1600 10.1182/blood-2025-1600

Abstract Background: Older patients with acute myeloid leukemia (AML) are a particularly difficult-to-treat population, owing to the higher...

Bilateral optic nerve infiltration in pediatric ACUTE promyelocytic leukemia: A RARE and aggressive CNS relapse with probable ATRA resistance

Dylan Ron, Betty Vega, Marcos Di Stefano et al. Nov 03, 2025 pp. 7042-7042 10.1182/blood-2025-7042

Abstract Optic nerve leukemic infiltration is an exceptionally rare manifestation of acute promyelocytic leukemia (APL, AML-M3), especially...

Incidence and clinical outcomes of hematologic immune-related toxicities in patients with solid malignancies treated with immune checkpoint inhibitors

Andrew Bueno, Pedro Luiz Lage Bodour Danielian, Rebecca Karp et al. Nov 03, 2025 pp. 6235-6235 10.1182/blood-2025-6235

Abstract Introduction Immune checkpoint inhibitors (ICIs) are antineoplastic agents that mediate anticancer effects by u...

Distinct immune profiles among patients with primary effusion lymphoma and other kaposi sarcoma herpesvirus-associated diseases

Matthew Witterholt, Jose Mercado-Matos, Romin Roshan et al. Nov 03, 2025 pp. 7094-7094 10.1182/blood-2025-7094

Abstract Introduction Kaposi sarcoma herpesvirus (KSHV), also known as human herpesvirus 8 (HHV8), causes Kaposi sarcoma (KS), multicentric...

U.S. mortality trends in acquired aplastic anemia, 1999–2021: A joinpoint analysis using CDC wonder data

Emmanuel Ekpenyong, Meghana Kakarla Nov 03, 2025 pp. 7986-7986 10.1182/blood-2025-7986

Abstract Background Acquired aplastic anemia (AAA) is an immune-mediated marrow failure syndrome with high early mortality. Survival has imp...

Multiomic correlates of ex vivo αCD19 chimeric antigen receptor T-cell (CART) cytotoxicity in venetoclax-treated patients with chronic lymphocytic leukemia (CLL)

Jacob Wright, Francisco Hernandez-Ilizaliturri, Cory Mavis et al. Nov 03, 2025 pp. 5661-5661 10.1182/blood-2025-5661

Abstract Introduction: Chronic Lymphocytic Leukemia (CLL) results in the expansion of immunosuppressive B-cells leading...

Golidocitinib-based therapy in relapsed/refractory mycosis fungoides and Sézary syndrome: A real-world retrospective analysis

Qian Wang, Shu Wang, Qinyuan Zhu et al. Nov 03, 2025 pp. 8079-8079 10.1182/blood-2025-8079

Abstract Cutaneous T-cell lymphoma (CTCL) is an incurable malignancy of skin-tropic malignant CD4+ T cells, with mycosis fungoides (MF; indo...

Real-world treatment patterns and biomarker utilization among patients aged ≥65 years with CLL/SLL from 2020 to 2024

Paul Hampel, Daniel Ermann, Xiaoliang Wang et al. Nov 03, 2025 pp. 2723-2723 10.1182/blood-2025-2723

Abstract Background Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is the most common leukemia in US adults and incidence...

Roginolisib (IOA-244), an orally bioavailable, selective PI3Kδ inhibitor, in combination with venetoclax and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL)

Jennifer Brown, Robert Black, Hang Phan et al. Nov 03, 2025 pp. 3913-3913 10.1182/blood-2025-3913

Abstract Background and Significance Preclinical work established the synergy of BCL-2 inhibitors with phosphoinositide 3-kinase (PI3K) inhib...

Subcutaneous cevostamab demonstrates manageable safety and clinically meaningful activity in Relapsed/Refractory multiple myeloma (RRMM): First results from the Phase Ib CAMMA 3 study

Phoebe Joy Ho, Hang Quach, Sosana Delimpasi et al. Nov 03, 2025 pp. 700-700 10.1182/blood-2025-700

Abstract Background: Fc receptor-homolog 5 (FcRH5) is a type I membrane protein that is ubiquitously expressed on multiple myeloma (MM) cell...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page